Meropenem/vaborbactam

Meropenem/vaborbactam
Combination of
MeropenemBeta-lactam antibiotic
VaborbactamBeta-lactamase inhibitor
Clinical data
Trade namesVabomere, Vaborem, others
AHFS/Drugs.comMonograph
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia.[2][3][4] It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor.[4] It is given by injection into a vein.[4]

Common side effects include headache, inflammation at the site of injection, nausea, diarrhea, liver inflammation, and low blood potassium.[4] Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea.[4] It is unclear if use during pregnancy is safe.[5] Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some beta-lactamases.[4]

The combination was approved for medical use in the United States in 2017,[6] in the European Union in 2018,[4][3] and in Canada in December 2024.[7] It is on the World Health Organization's List of Essential Medicines.[8]

  1. ^ "Summary Basis of Decision for Vabomere". Drug and Health Products Portal. 4 April 2025. Retrieved 10 July 2025.
  2. ^ a b "Vabomere- meropenem-vaborbactam injection, powder, for solution". DailyMed. 19 October 2023. Retrieved 26 July 2024.
  3. ^ a b c "Vaborem EPAR". European Medicines Agency. 24 September 2018. Retrieved 6 November 2019.
  4. ^ a b c d e f g "Vabomere (combination) Monograph for Professionals". Drugs.com. Retrieved 6 November 2019.
  5. ^ "Meropenem / vaborbactam (Vabomere) Use During Pregnancy". Drugs.com. Retrieved 6 November 2019.
  6. ^ Cite error: The named reference FDA PR 20170829 was invoked but never defined (see the help page).
  7. ^ "Register of Innovative Drugs". Health Canada. 13 January 2025. Retrieved 15 January 2025.
  8. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.